KRAS and pancreatic intraductal papillary-mucinous neoplasm: In the progression from IPMN into the “IPMN derived from” invasive carcinoma (IPMC), further molecular alterations are found, including early KRAS mutations (in approximately 65% of gastric-type IPMNs) [42].